Low viral titers and inefficient transduction
Pre-existing immunity to common viral serotypes
Scalability and cost of manufacturing for clinical trials
Safety risks of insertional mutagenesis or recombination
AAV2, AAV5, AAV6, AAV8, AAV9 and other serotypes with custom transgene packaging.
Third-generation, VSV-G pseudotyped lentivirus for in vitro and in vivo use.
A choice of ubiquitous, tissue-specific, or inducible promoters.
Services include functional titering, purity analysis, and sterility testing.
Access to a wide range of AAV and lentiviral options.
Processes optimized for high viral yields.
Biosafety level compliant production and handling of viral vectors.
Experts in virology and vectorology to support your project design.
Rapid and Efficient
Stay updated with the latest industry news and expert insights.
Subscribe now to receive:
● Industry updates
● Exclusive expert insights and analysis
Enter your email to stay ahead!
